Shandong Sinobioway Biomedicine Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jialin Yue

Chief executive officer

CN¥1.8m

Total compensation

CEO salary percentage	n/a
CEO tenure	2.3yrs
CEO ownership	n/a
Management average tenure	2.3yrs
Board average tenure	2.3yrs

Recent management updates

Recent updates

CEO

Jialin Yue (56 yo)

2.3yrs

Tenure

CN¥1,775,200

Compensation

Mr. Jialin Yue is GM & Director of Shandong Sinobioway Biomedicine Co., Ltd. since July 9, 2022 and August 5, 2022 respectively and was its Co-GM since April 10, 2022 until August 5, 2022. He serves as Cha...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jialin Yue	Chairman & GM	2.3yrs	CN¥1.78m	no data
Wenjun Liu	Deputy GM & Non-Independent Director	2.3yrs	CN¥1.02m	no data
Hui Zhao	Board Secretary & Employee Director	2.6yrs	CN¥1.16m	no data
Wenyu Zhang	Deputy General Manager	1.3yrs	CN¥625.40k	no data
Ren Yanshen	Co-Founder	no data	no data	no data
Chen Zhangliang	Co-Founder	no data	no data	no data

2.3yrs

Average Tenure

55.5yo

Average Age

Experienced Management: 002581's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jialin Yue	Chairman & GM	2.3yrs	CN¥1.78m	no data
Wenjun Liu	Deputy GM & Non-Independent Director	2.3yrs	CN¥1.02m	no data
Hui Zhao	Board Secretary & Employee Director	2.3yrs	CN¥1.16m	no data
Xiuyuan Yu	Vice Chair	8.9yrs	CN¥813.80k	no data
Xue Ming Yan	Member of the Supervisory Board	8.9yrs	no data	no data
Wenjie Yu	Director	2.3yrs	CN¥649.90k	no data
Guiyuan Huang	Non-Independent Director	2.3yrs	CN¥531.00k	no data
Yang Liu	Independent Director	2.3yrs	no data	no data
Jie Xiao	Independent Director	2.3yrs	CN¥100.00k	no data
Yang Xia	Independent Director	2.3yrs	CN¥100.00k	no data

2.3yrs

Average Tenure

52.5yo

Average Age

Experienced Board: 002581's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Shandong Sinobioway Biomedicine Management

Management criteria checks 1/4

Key information

Recent management updates

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, May 22, 2024

Shandong Sinobioway Biomedicine Co., Ltd. Announces Executive Appointments

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, Aug 22, 2022

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.067 (vs CN¥0.13 in 3Q 2023)

Shandong Sinobioway Biomedicine Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.003 loss per share (vs CN¥0.049 loss in 2Q 2023)

Shandong Sinobioway Biomedicine Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

First quarter 2024 earnings released: CN¥0.042 loss per share (vs CN¥0.033 loss in 1Q 2023)

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, May 22, 2024

Shandong Sinobioway Biomedicine Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Shandong Sinobioway Biomedicine Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.061 in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.049 loss per share (vs CN¥0.033 profit in 2Q 2022)

Full year 2022 earnings released: CN¥0.022 loss per share (vs CN¥0.41 profit in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.061 (vs CN¥0.32 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.17 in 2Q 2021)

Shandong Sinobioway Biomedicine Co., Ltd. Announces Executive Appointments

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, Aug 22, 2022

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.037 in 1Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.021 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.045 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.29 loss per share (vs CN¥0.096 profit in FY 2019)

New 90-day low: CN¥9.90

New 90-day low: CN¥12.64

New 90-day low: CN¥15.21

New 90-day low: CN¥17.15

Third quarter earnings released

Shandong Sinobioway Biomedicine Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Beijing Fourth Intermediate People's Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan

New 90-day low: CN¥17.55

First half earnings released

New 90-day low - CN¥19.50

Shandong Sinobioway Biomedicine Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age